Barclays Starts Chiasma (CHMA) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- S&P 500, Nasdaq futures rise as AI stocks rebound ahead of key earnings
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil slips from five-month high with Hormuz transits in focus
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- Microsoft pulls out of UK data center deal with Nscale, Telegraph reports
- S&P 500, Nasdaq futures rise as AI stocks rebound ahead of key earnings
- Lithuanians forced to take shelter after suspected drone enters airspace
- AST SpaceMobile partners with four European operators on MSS spectrum
William Blair Starts Chiasma (CHMA) at Outperform
August 10, 2015 7:28 AM EDTWilliam Blair initiated coverage on Chiasma (NASDAQ: CHMA) with an Outperform rating and a price target of $40.00.
For an analyst ratings summary and ratings history on Chiasma click here. For more ratings news on Chiasma click here.
Shares of Chiasma closed at $23.83 yesterday.
... MoreCowen Starts Chiasma (CHMA) at Outperform
August 10, 2015 6:25 AM EDTCowen initiates coverage on Chiasma (NASDAQ: CHMA) with a Outperform rating and a price target of $43.00.
Analyst Ritu Baral commented, "We think Chiasma's TPE-Octreotide will become a key acromegaly treatment in the US/EU. We expect FDA to approve TPE-Octreotide in mid 2016,... More



